Clinical Trials Logo

Clinical Trial Summary

This study will assess the potential of Testagen® TDS-Testosterone to enable transfer of Testosterone to females coming in contact with skin to which Testagen® TDS-Testosterone has been applied and the potential of product to raise serum androgen levels in those women.


Clinical Trial Description

48 Couples will be added to the protocol and a single dose applied by the male member of the couple. The female member of the couple will have undergone a baseline pharmacokinetic monitoring of her endogenous levels of Testosterone. At precise intervals by cohort on the day of the trial, the male will expose the skin onto which the trial materials were applied to the skin of his partner and she will then undergo another 24-hour multiple sample monitoring of her levels of testosterone. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02733133
Study type Interventional
Source Transdermal Delivery Solutions Corp
Contact
Status Enrolling by invitation
Phase Phase 2
Start date November 2016
Completion date December 2024

See also
  Status Clinical Trial Phase
Not yet recruiting NCT01894308 - A Dose Ranging Study to Examine TDS-Testosterone 5% Phase 2